Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,302 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06984562Recruiting
Adaptive radiation therapy for advanced pancreatic cancer
This trial tests a new way of giving radiation therapy that adapts to changes in your cancer over time. It is for people with pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Phoenix, ArizonaAges 18 years+ - NCT06288373RecruitingPhase 2/Phase 3
Comparing chemoimmunotherapy vs chemoradiation for advanced cervical cancer before surgery
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
Hefei, AnhuiAges 18–70 - NCT06482086RecruitingPhase 2
Using tumor models to guide drug choice for advanced thyroid cancer
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
Chengdu, SichuanAges 18 years+ - NCT07455617RecruitingPhase 1
Vaccine for KRAS-mutated advanced solid tumors
This trial tests a new vaccine, ABO2102, for people with advanced solid tumors that have a specific change in the KRAS gene. The vaccine aims to help your immune system fight the cancer.
ShanghaiAges 18 years+ - NCT06288360RecruitingPhase 2
Chemo plus immunotherapy before surgery for PD-L1-negative cervical cancer
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
Hefei, AnhuiAges 18–70 - NCT06063681RecruitingPhase 1
Testing a new ENPPI inhibitor for advanced solid tumors
This trial tests a new drug, SR-8541A, that blocks an enzyme called ENPPI, which may help slow or stop tumor growth. It is for people with advanced or metastatic solid tumors who have not responded to other treatments or have no standard options.
Randwick, New South WalesAges 18 years+ - NCT07876609RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug, BA1203, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and whether it can help shrink tumors.
BeijingAges 18–75 - NCT05650242RecruitingPhase 1
Study of BA1106 in people with advanced solid tumors
This study tests an experimental drug called BA1106 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe, tolerable, and whether it can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06166888RecruitingPhase 1
Study of AK131 for advanced solid tumors
This trial tests a new drug called AK131 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and can help slow or shrink the cancer.
Jinan, ShandongAges 18 years+ - NCT06248697RecruitingEarly Phase 1
CAR-T cells targeting MSLN with PD-1/CTLA-4 blockers for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07813000Recruiting
Patient and doctor views on cell therapies for advanced cancer
This study is a survey to learn about what patients and doctors think about newer cell-based cancer treatments (like CAR-T or TIL therapy). You will answer questions about your experiences and preferences, which will help guide future research.
Hangzhou, ZhejiangAges 18 years+ - NCT07800936RecruitingPhase 1
Injecting drug HP007 for advanced solid tumors that stopped responding to treatment
This trial tests an injected drug directly into tumors for people with advanced solid tumors like breast, head and neck, melanoma, prostate, or liver cancer that have not responded to standard treatments. It may help shrink tumors or slow their growth.
Changchun, JilinAges 18–75 - NCT05831033RecruitingEarly Phase 1
Your own immune T-cells to treat advanced solid tumors
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06117540RecruitingPhase 2
WX390 for advanced solid tumors after standard treatment
This trial tests a new drug called WX390 for people whose advanced solid tumors have not responded to standard treatments. The study aims to see if WX390 can help shrink or slow the growth of these tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06695689RecruitingEarly Phase 1
LM303 injection for advanced solid tumors
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
TianjinAges 18 years+ - NCT06117566RecruitingPhase 1/Phase 2
WX390 plus Toripalimab for advanced solid tumors
This trial tests a combination of two investigational drugs, WX390 and Toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Changchun, JilinAges 18 years+ - NCT07487597RecruitingEarly Phase 1
Engineered T cell therapy for ALPP-positive advanced solid tumors
This trial tests a new type of immune cell therapy designed to target and attack cancer cells that have a specific marker called ALPP. It is for people with advanced solid tumors who have not responded to or cannot have standard treatments.
Nanjing, JiangsuAges 18–70 - NCT07382531RecruitingPhase 1/Phase 2
OH2 and BS006 injection for advanced solid tumors
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07284992RecruitingPhase 2
Comparing short vs long radiation with immunotherapy for rectal cancer
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Jinan, ShandongAges 18–80 - NCT07274085RecruitingPhase 1
Study of HDM2017 for advanced solid tumors
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07265622RecruitingPhase 1/Phase 2
Study of 7MW4911 for advanced solid tumors
This trial tests a new drug called 7MW4911 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a tumor that expresses a certain protein (CDH17).
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07253116RecruitingPhase 1/Phase 2
Study of WJ22096 tablets for advanced solid tumors
This trial tests a new oral drug (WJ22096) for people with advanced solid tumors that have stopped responding to or cannot tolerate standard treatments. It may be an option if you are generally healthy enough to take part.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07258121RecruitingPhase 1/Phase 2
ZGGS34 for Advanced Solid Tumors Targeting MUC17
This trial tests an experimental drug called ZGGS34 that targets a protein (MUC17) found on some cancer cells. It is designed for people with advanced solid tumors (stomach, pancreas, colorectal, or other) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–75
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,302 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.